The court found that this commercial practice did not constitute a violation of Sec. 4 no. 1 UWG (the German Unfair Competition Act), because the plaintiff could not prove that the granted benefits impaired the doctor's independent decision in regard to his prescription practice.
First of all, the court found that the respective benefit was not high enough to put a pressure on the doctors' right to freely decide on their prescriptions. Furthermore, the pharmaceutical company would not be informed about the prescriptions of the doctors. Also, under social law regulations, doctors must take into account the cost-effectiveness of drugs, so that they would not prescribe the products of the pharmaceutical company if equivalent drugs of competitors are less expensive.
Volltext: Volltext